BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Treatment
7999 results:

  • 1. Antiproliferative and Apoptotic Effects of Murici (Byrsonima crassifolia (L.) Kunth and verbascifolia (L.) DC) and Taperebá (Spondias mombin L.) Extracts in Human prostate Cell Line (PC-3).
    Amaral Muxfeldt Paim TOD; Simas NF; Abreu JP; Rosa L; Passos Barbosa Lima T; Teodoro AJ
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1339-1347. PubMed ID: 38679995
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Patient-Derived Xenograft Models for Translational prostate cancer Research and Drug Development.
    Philp LK
    Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
    Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
    Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
    Elife; 2024 Apr; 13():. PubMed ID: 38656229
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Developing a Novel Enzalutamide-Resistant prostate cancer Model via AR F877L Mutation in LNCaP Cells.
    Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
    Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
    Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
    Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
    Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
    Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
    Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
    Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Isolation, Identification and Chemical Modification of Bufadienolides from
    Ye Q; Lin R; Chen Z; Li J; Zheng C
    Molecules; 2024 Mar; 29(7):. PubMed ID: 38611850
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy.
    Feng DC; Zhu WZ; Wang J; Li DX; Shi X; Xiong Q; You J; Han P; Qiu S; Wei Q; Yang L
    Mil Med Res; 2024 Apr; 11(1):21. PubMed ID: 38605399
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.
    Ribeiro CF; Rodrigues S; Bastos DC; Fanelli GN; Pakula H; Foiani M; Zadra G; Loda M
    Sci Signal; 2024 Apr; 17(831):eadh1922. PubMed ID: 38593154
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells.
    Atri Roozbahani G; Kokal-Ribaudo M; Heidari Horestani M; Pungsrinont T; Baniahmad A
    Cell Commun Signal; 2024 Apr; 22(1):219. PubMed ID: 38589887
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
    Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
    Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
    PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Is fibroblast growth factor 11 (FGF11) a predictive marker for breast cancer?
    Aktürk Esen S; Karabulut S; Buyukaksoy M; Kurt Cevik G; Ceylan F; Civelek B; Şendur MAN; Erdogan F; Uncu D
    Medicine (Baltimore); 2024 Mar; 103(13):e37656. PubMed ID: 38552037
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Safety of Docetaxel in a Patient with Metastatic Castration-Resistant prostate cancer After Kidney Transplantation: A Case Report.
    Nagahisa C; Iizuka J; Kobari Y; Minoda R; Oki R; Unagami K; Yoshida K; Hirai T; Omoto K; Shimizu T; Ishida H; Takagi T
    Transplant Proc; 2024 Apr; 56(3):729-733. PubMed ID: 38548511
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Rosmarinic Acid-Rich
    Netala VR; Hou T; Sana SS; Li H; Zhang Z
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542889
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic prostate cancer.
    Uzelac M; Xin R; Ongkeko WM
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of prostate cancer.
    Salamini-Montemurri M; Vizoso-Vázquez Á; Barreiro-Alonso A; Lorenzo-Catoira L; Rodríguez-Belmonte E; Cerdán ME; Lamas-Maceiras M
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542079
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 400.